|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
άA�� |
| ��������������� | |
|
����� |
|
������ |
|
��־ǿ |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
άA����ҩ��ϵͳ��ҩ�ij���������Ӧ����Բ�
�����, ������, ��־ǿ
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ� 210042
άA����ҩ����Ƥ�����ٴ������е�������������,�䲻����ӦҲ�����ܵ����ǵ�����.�����˴���ҩ��ϵͳʹ�õij���������Ӧ��Ԥ�������ƴ�ʩ,�Ӷ�����ҽ���ͻ�����Ч����ȫ��ʹ�ô���ҩ��,���õط���������������,���ٲ�����Ӧ�ķ���.
[2] Bickers DR,Saurat JH.Isotretinoin:A state-of-the-art conference.J Am Acad Dermatol,2001,45(5):S125-128
[3] Kochhar DM,Christian MS.Tretinoin:a review of the nonclinical developmental toxicology experience.J Am Acad Dermatol,1997,36(3Pt 2):S47-59.
[4] Nau H.Teratogenicity of isotretinoin revisited:species variation and the role of all-trans-retinoic acid.J Am Acad Dermatol,2001,45(5):S183-187.
[5] Gollnick HP.Oral retinoids-efficacy and toxicity in psoriasis.Br J Dermatol,1996,135(Suppl 49):6-17.
[6] Sturkenboom MC,de Jong-Van Den Berg LT,van Voorst-Vader PC,et al.Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment.Br J Clin Pharmacol,1994,38(3):229-235.
[7] Wysowski DK,Pitts M,Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin.J. Am Acad Dermatol,2001,45(4):515-519.
[8] Jacobs DG,Deutsch NL,Brewer M.Suicide,depression,and isotretinoin:is there a causal link? J Am Acad Dermatol,2001,45(5):S168-175.
[9] Wysowski DK,Swann J,Vega A.Use of isotretinoin(Accutane)in the United States:rapid increase from 1992 through 2000.J Am Acad Dermatol,2002,46(4):505-509.
[10] Hammer CJ 3rd,Carter CC,Hanifin JM.Peripheral neuropathy during etretinate therapy for psoriasis.J Am Acad Dermatol,1993,28(2Pt 1):272-273.
[11] Lister RK,Lecky BR,Lewis-Jones MS,et al.Acitretin-induced my opathy.Br J Dermatol,1996,134(5):989-990.
[12] Chroni E,Georgiou S,Monastirli A,et al.Effects of short-term oral acitretin therapy on peripheral nerve function:a prospective neurological and neurophysiological study.Acta Derm Venereol,2001,81(6):423-425.
[13] Dicken CH.Retinoids:a review.J Am Acad Dermatol,1984,11(4Pt 1):541-552.
[14] Heudes AM,Laroche L.Muscular damage during isotretinoin treatment.Ann Dermatol Venereol,1998,125(2):94-97.
[15] Landau M,Mesterman R,Ophir J,et al.Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin.Acta Derm Venereol,2001,81(5):350-352.
[16] Lestringant GG,Frossard PM,Agarwal M,et al.Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL-cholesterol.Int J Dermatol,1997,36(11):859-862.
[17] Alcalay J,Landau M,Zucker A.Analysis of laboratory data in acne patients treated with isotretinoin:is there really a need to perform routine laboratory tests? J Dermatolog Treat,2001,12(1):9-12.
[18] Altman RS,Altman LJ,Altman JS.A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris.Dermatology,2002,204(3):232-235.
[19] Stem RS,Fitzgerald E,Ellis CN,et al.The safety of etretinate as long-term therapy for psoriasis:results of the etretinate follow-up study.J Am Acad Dermatol,1995,33(1):44-52.
[20] Mills CM,Marks R.Etretinate hepatitis.J Dermatolog Treat,1994,5:145-146.
[21] Ellis CN,Krach KJ.Uses and complications of isotretinoin therapy.J Am Acad Dermatol,2001,45(5):S150-157.
[22] Goulden V,Layton AM,Cunliffe WJ.Long-term safety of isotretinoin as a treatment for acne vulgaris.Br J Dermatol,1994,131(3):360-363.
[23] Salasche SJ,Lebwohl M.Clinical pearl:vitamin E(alpha-tocopherol),800 IU daily,may reduce retinoid toxicity.J Am Acad Dermatol,1999,41(2Pt 1):260.
[24] Strauss JS,Gottlieb AB,Jones T,et al.Concomitant administration of vitamin E does not change the side effects of isotretinoin as used in acne vulgaris:a randomized trial.J Am Acad Dermatol,2000,43(5Pt 1):777-784.